This is a rerecording of a recent workshop on D and C procedure that I did with my residents. Enjoy!
If you would like to use this prezi for your residents, let me know and I can send you the file. All I ask is a mention of the blog in your presentation!
Due to a death in the family I have not had much time recently to work on the blog and podcast. I have not forgotten you all and all the support you have given, and am committed to making 2010 the biggest year yet for Academic OB/GYN! But for the moment, it is on break. I hope to get back to it in the next 3-4 weeks.
Nicholas Fogelson, MD
Early reports described the story of Tracy Hermanstorfer as a “Christmas Miracle”. It has also been described as inspiring, heartwarming, and “wonderfully appropriate for the season.” Others have referred to her saga as a nightmare with a happy ending.
On Christmas Eve 2009, Ms. Hermanstorfer was admitted to Memorial Hospital in Colorado Spring, Colorado after her water broke. Ms. Hermanstorfer suffered a cardiac arrest during labor with her child Colton. After immediate resuscitative efforts failed, nearby Maternal Fetal Medicine physician (Dr Stephanie Martin) performed an emergency cesarean section. In the minutes following the delivery, Ms Hermanstorfer regained circulation and breathing, and is now doing well. Her infant also went on to survive and is apparently well.
When Ortho Evra, the contraceptive patch came on the market, physicians were happy that women had a new and novel contraceptive method that significantly expanded options over what was already available. Since that time, hundreds of thousands of women worldwide have safely used Ortho Evra for birth control.
As the transdermal patch was a new delivery method for birth control, several new pharmacokinetic studies were done postmarketing, in addition to those done prior to FDA approval. One of these studies demonstrated that patients using Ortho Evra had on average 60% higher estrogen blood levels than patients on oral contraceptives, despite lower peak levels (1). Given that estrogen somewhat increases the risk of venous thromboembolism(VTE), this data raised the concern that Ortho Evra might confer a greater attributable risk than traditional oral contraceptives.